1a. Objectives (from AD-416):
The objective of this effort is to support the engagement of USDA collaborative research with ILRI and National research institutions engaged in research that addresses the development of new generation vaccines, diagnostic tests, management strategies and drugs for diseases of critical importance including Rift Valley fever (RVF), MCF, foot-and-mouth disease (FMD), and other diseases of strategic importance.
1b. Approach (from AD-416):
ILRI will participate in and help support activities that underpin the establishment and implementation of collaborative research and supporting activities, such as establishing sub agreements with relevant NARS, developing publications, co-organizing and supporting attendance at meetings and facilitating working groups that support research cooperation that would help to meet the objective. These activities will be identified in consultation with, and under the agreement of, the ADODR and ARS cooperators.
3. Progress Report:
Progress was obtained through meetings, telecoms and regular email communication between key ILRI and ARS staff. The last year has seen a continuation of active dialog and engagement between ILRI and USDA-ARS to consolidate and develop new research activities in alignment with the restructuring of the CGIAR system and ILRI’s development of the CGIAR Research Programs (Livestock and Fish, and Nutrition and Health), as well as developing additional collaborative projects with USDA-ARS. East Coast Fever: a workshop held at ILRI in April 2012 led to submission of a concept note to the Bill and Melinda Gates Foundation (BMGF) in August 2012, which led to an invitation to submit a full proposal. A consortium approach based proposal was submitted in February 2013. The project title is “Improved vaccines for the control of East Coast Fever in cattle in Africa”. Since then two rounds of iterations of the proposal have been completed, including responses to external and internal scientific and budget reviews with the final response submitted 24th June 2013. The total estimated cost of the project over a four-year period is USD 15 million with USD11 million requested from BMGF. The NBCRI and the BMGF projects on ECF will be aligned with each other. Funds have been used to hire laboratory technician to support the NBRCI funded project on ECF. FMD: ILRI continues to support and participate in the Global Foot-and-Mouth Disease Research Alliance (GFRA). Brucella: ILRI, ARS and USAID partnered to organize a workshop entitled “An integrated approach to controlling brucellosis in Africa” held at ILRI campus in Addis Ababa, 29th-31st January 2013. A report of this workshop was prepared is available on the ILRI website http://cgspace.cgiar.org/handle/10568/32734. ASF: ILRI staff met with ARS scientists and wider scientific community at Plum Island, 3-5th April 2013, during a workshop on Africa Swine Fever and were present during the launch of GARA, a Global African Swine Fever Research Alliance. This visit led to ASF research opportunities being discussed between DHS, USAD-ARS and ILRI. ILRI is a signatory to GARA. Follow up: ILRI and ARS staff met in Nairobi in June 2013 during a DTRA-supported scoping mission. Plans were made to meet in Pullman, WA and to engage with other USDA-ARS labs. USDA-DOD-ILRI discussions revolved around the Cooperative Biosecurity Engagement Program (CBEP) mission and possible roles for various institutions and opportunities in teaching, training and capacity development in biosecurity related matters. The group toured ILRI research, laboratory and farm facilities, including BSL3 laboratory and secure animal disease facility (enhanced BSL2).